Composition and kit for detecting RNA (Ribonucleic Acid) virus based on third-generation targeted sequencing and application of composition and kit
Through the composition and kit based on three generation targeted sequencing, reverse transcription and multiple PCR amplification using multiple primer combinations, the problem of difficulty in detecting multiple pathogenic microorganisms at the same time in the prior art was solved, and 75 RNA viruses were achieved The rapid and accurate distinction and identification improves detection efficiency and resolution.
Patent Information
- Application Number
- CN202411086453.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of methods in the prior art that can detect multiple pathogenic microorganisms quickly and accurately at the same time. Multiple PCR amplification technology is mainly used for the detection of single or several pathogenic microorganisms, and it is difficult to amplify and distinguish multiple pathogenic microorganisms simultaneously.
Provide a composition and kit based on three generation targeted sequencing, which contains a variety of primer combinations, which can amplify and distinguish 75 RNA viruses, including rubella virus, dengue virus, coxsackie virus, etc., through retro transcription and multiple PCR Amplification, library construction and sequencing analysis enable rapid identification.
Simultaneous amplification and rapid and accurate distinction and identification of 75 pathogenic microorganisms have been achieved, detection efficiency and resolution have been improved, and the difficulties in detecting multiple pathogenic microorganisms in the prior art have been overcome.
Smart Images

Figure CN118910330A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biological detection, and specifically relates to a composition, a kit and an application thereof for detecting RNA viruses based on third-generation targeted sequencing. Background Art
[0002] Multiplex PCR amplification technology has been intensively studied due to its high efficiency, high throughput and low cost. Since the concept of multiplex PCR amplification was first proposed in 1988, multiplex PCR amplification has been applied to many fields, including gene mutation and deletion, gene typing and quantification, genetic testing, companion drug diagnosis, etc.
[0003] The multiplex PCR technology that uses specific primers to amplify and detect pathogenic microorganisms has become an indispensable means of pathogen detection. Multiplex PCR can amplify and capture all currently known pathogenic microorganisms, and can effectively improve the resolution and strong anti-interference properties.
[0004] Currently, there are reports in the prior art on the use of multiplex PCR amplification technology to detect one or several pathogenic microorganisms, but there are few reports on the use of multiplex PCR amplification technology to detect multiple pathogenic microorganisms at the same time. Summary of the invention
[0005] The present invention provides a composition, a kit and applications thereof for detecting RNA viruses based on third-generation targeted sequencing. The kit can rapidly and accurately detect and differentiate a variety of pathogenic microorganisms.
[0006] In the first aspect, the present invention provides a composition for detecting RNA viruses based on third-generation targeted sequencing, characterized in that it comprises at least two combinations of the following primer sets: a primer set for amplifying rubella virus as shown in SEQ ID NOs: 1 to 6; a primer set for amplifying dengue virus type 2 as shown in SEQ ID NOs: 7 to 12; a primer set for amplifying dengue virus type 3 as shown in SEQ ID NOs: 13 to 18; a primer set for amplifying coxsackievirus B6 as shown in SEQ ID NOs: 19 to 24; a primer set for amplifying human T-cell virus type I as shown in SEQ ID NOs: 25 to 30; a primer set for amplifying coxsackievirus B2 as shown in SEQ ID NOs: 31 to 38; a primer set for amplifying tick-borne encephalitis virus as shown in SEQ ID NOs: 39 to 44; a primer set for amplifying yellow fever virus as shown in SEQ ID NOs: 45 to 48; a primer set for amplifying coxsackievirus B5 as shown in SEQ ID NOs: 49 to 54; a primer set for amplifying The primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs:55 to 60; the primer set for amplifying hepatitis E virus as shown in SEQ ID NOs:61 to 68; the primer set for amplifying Xinjiang hemorrhagic fever virus as shown in SEQ ID NOs:69 to 74; the primer set for amplifying SARS virus as shown in SEQ ID NOs:75 to 80; the primer set for amplifying Sabia virus as shown in SEQ ID NOs:81 to 90; the primer set for amplifying human coronavirus OC43 as shown in SEQ ID NOs:91 to 96; the primer set for amplifying Coxsackie virus A2 as shown in SEQ ID NOs:97 to 102; the primer set for amplifying Coxsackie virus A9 as shown in SEQ ID NOs:103 to 110; the primer set for amplifying enterovirus D70 as shown in SEQ ID NOs:111 to 116; the primer set for amplifying influenza C virus as shown in SEQ ID NOs:117 to 120; The primer set for amplifying Rift Valley fever virus as shown in SEQ ID NOs: 121 to 130; the primer set for amplifying human rhinovirus A as shown in SEQ ID NOs: 131 to 138; the primer set for amplifying human parechovirus type 1 as shown in SEQ ID NOs: 139 to 148; the primer set for amplifying coxsackievirus A16 as shown in SEQ ID NOs: 149 to 156; the primer set for amplifying human parainfluenza virus type 4b as shown in SEQ ID NOs: 157 to 168; the primer set for amplifying human astrovirus as shown in SEQ ID NOs: 169 to 176; the primer set for amplifying thrush coronavirus HKU12 as shown in SEQ ID NOs: 177 to 184; the primer set for amplifying Munia coronavirus HKU13 as shown in SEQ ID NOs: 185 to 190;A primer set for amplifying human parechovirus type 3 as shown in SEQ ID NOs: 191 to 198; a primer set for amplifying enterovirus type A71 as shown in SEQ ID NOs: 199 to 206; a primer set for amplifying human metapneumovirus as shown in SEQ ID NOs: 207 to 214; a primer set for amplifying coxsackievirus type A6 as shown in SEQ ID NOs: 215 to 222; a primer set for amplifying human immunodeficiency virus as shown in SEQ ID NOs: 223 to 232; a primer set for amplifying influenza A virus H7N9 as shown in SEQ ID NOs: 233 to 248; a primer set for amplifying Ebola virus as shown in SEQ ID NOs: 249 to 258; a primer set for amplifying enterovirus type D68 as shown in SEQ ID NOs: 259 to 268; a primer set for amplifying a novel bunyavirus as shown in SEQ ID NOs: 269 to 278; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 280 to 281; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 281 to 283; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 284 to 285; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 286 to 287; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 288 to 291; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 293 to 294; a primer set for amplifying a novel avian virus as shown in SEQ ID NOs: 297 a primer set for amplifying human respiratory syncytial virus type B as shown in SEQ ID NOs: 279 to 288; a primer set for amplifying hepatitis C virus type 1b as shown in SEQ ID NOs: 289 to 296; a primer set for amplifying Japanese encephalitis virus as shown in SEQ ID NOs: 297 to 302; a primer set for amplifying human T-cell lymphotropic virus type II as shown in SEQ ID NOs: 303 to 312; a primer set for amplifying hepatitis A virus as shown in SEQ ID NOs: 313 to 320; a primer set for amplifying coxsackievirus type B3 as shown in SEQ ID NOs: 321 to 328; a primer set for amplifying human respiratory syncytial virus type A as shown in SEQ ID NOs: 329 to 334; a primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 335 to 342; a primer set for amplifying dengue virus type 1 as shown in SEQ ID NOs: 343 to 348; a primer set for amplifying dengue virus type 2 as shown in SEQ ID NOs: 350 to 351; a primer set for amplifying dengue virus type 3 as shown in SEQ ID NOs: 352 to 353; a primer set for amplifying dengue virus type 4 as shown in SEQ ID NOs: 354 to 355; a primer set for amplifying dengue virus type 5 as shown in SEQ ID NOs: 356 to 357; a primer set for amplifying dengue virus type 6 as shown in SEQ ID NOs: 357 to 358; a primer set for amplifying dengue virus type 7 as shown in SEQ ID NOs: 359 to 360; a primer set for amplifying dengue virus type 8 a primer set for amplifying human rhinovirus B as shown in SEQ ID NOs: 349 to 360; a primer set for amplifying measles virus as shown in SEQ ID NOs: 361 to 370; a primer set for amplifying rabies virus as shown in SEQ ID NOs: 371 to 378; a primer set for amplifying human parainfluenza virus type 3 as shown in SEQ ID NOs: 379 to 388; a primer set for amplifying influenza A virus H1N1 as shown in SEQ ID NOs: 389 to 400; a primer set for amplifying mumps virus as shown in SEQ ID NOs: 401 to 406; a primer set for amplifying influenza B virus as shown in SEQ ID NOs: 407 to 412; a primer set for amplifying dengue virus type 4 as shown in SEQ ID NOs: 413 to 420; a primer set for amplifying human parainfluenza virus type 2 as shown in SEQ ID NOs: 421 to 430; a primer set for amplifying human parainfluenza virus type 1 as shown in SEQ ID NOs: 431 to 440;Primer groups for amplifying Eastern equine encephalitis virus as shown in SEQ ID NOs: 441 to 456; primer groups for amplifying Banna virus as shown in SEQ ID NOs: 457 to 466; primer groups for amplifying lymphochoriomeningitis virus as shown in SEQ ID NOs: 467 to 476; primer groups for amplifying Hantavirus as shown in SEQ ID NOs: 477 to 482; primer groups for amplifying human coronavirus NL63 as shown in SEQ ID NOs: 483 to 490; primer groups for amplifying influenza A virus H5N1 as shown in SEQ ID NOs: 491 to 500; primer groups for amplifying influenza A virus H3N2 as shown in SEQ ID NOs: 501 to 510; primer groups for amplifying human rhinovirus C as shown in SEQ ID NOs: 511 to 518; primer groups for amplifying Zika virus as shown in SEQ ID NOs: 519 to 524; primer groups for amplifying enterovirus A114 as shown in SEQ ID NOs: 525 to 532; Primer set for amplifying Coxsackievirus B3 as shown in SEQ ID NOs: 533 to 540; Primer set for amplifying Norovirus as shown in SEQ ID NOs: 541 to 548; Primer set for amplifying 2019 novel coronavirus as shown in SEQ ID NOs: 549 to 560; Primer set for amplifying human coronavirus HKU1 as shown in SEQ ID NOs: 561 to 568; Primer set for amplifying echovirus as shown in SEQ ID NOs: 569 to 574; Primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 575 to 580; Primer set for amplifying poliovirus 3 as shown in SEQ ID NOs: 581 to 586; Primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 587 to 594; Primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 595 to 604; Primer set for human coronavirus HKU1 as shown in SEQ ID NOs: 605 to 608. ;
[0007] In the present invention, at least two combinations of the above primer sets are included, for example, 2 combinations, 3 combinations, 4 combinations, 5 combinations, 6 combinations, 7 combinations, 8 combinations, 9 combinations, 10 combinations, 11 combinations, 12 combinations, 13 combinations, 14 combinations, 15 combinations, 16 combinations, 17 combinations, 18 combinations, 19 combinations, 20 combinations, 21 combinations, 22 combinations, 23 combinations, 24 combinations, 25 combinations, 26 combinations, 27 combinations, 28 combinations, 29 combinations, 30 combinations, 31 combinations, 32 combinations, 33 combinations, 34 combinations, 35 combinations, 36 combinations, 37 combinations, 38 combinations, 39 combinations, 40 combinations, 41 combinations, 42 combinations, 43 combinations, 44 combinations, 45 combinations, 46 combinations, 47 combinations, 48 combinations, 49 combinations, 50 combinations, 51 combinations, 52 combinations, 53 combinations, 54 combinations, 55 combinations, 56 combinations, 57 combinations, 58 combinations, 59 combinations, 60 combinations, 61 combinations, 62 combinations, 63 combinations, 64 combinations, 65 combinations, 66 combinations, 67 combinations, 68 combinations, 69 combinations, 70 combinations, 71 combinations, 72 combinations, 73 combinations, 74 combinations, 75 combinations.
[0008] In some embodiments, at least 30 combinations of primer sets are included.
[0009] In some embodiments, the primer sets include: a primer set for amplifying rubella virus as shown in SEQ ID NOs: 1 to 6; a primer set for amplifying dengue virus type 2 as shown in SEQ ID NOs: 7 to 12; a primer set for amplifying dengue virus type 3 as shown in SEQ ID NOs: 13 to 18; a primer set for amplifying coxsackie virus type B6 as shown in SEQ ID NOs: 19 to 24; a primer set for amplifying human T-cell lymphotropic virus type I as shown in SEQ ID NOs: 25 to 30; a primer set for amplifying coxsackie virus type B2 as shown in SEQ ID NOs: 31 to 38; a primer set for amplifying tick-borne encephalitis virus as shown in SEQ ID NOs: 39 to 44; a primer set for amplifying yellow fever virus as shown in SEQ ID NOs: 45 to 48; a primer set for amplifying coxsackie virus type B5 as shown in SEQ ID NOs: 49 to 54; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 55 to 60; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 56 to 61; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 57 to 62; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 58 to 64; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 59 to 70; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 65 to 71; a primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 66 to 73; a primer set for amplifying amplification of hepatitis E virus as shown in SEQ ID NOs: 61 to 68; amplification of Xinjiang hemorrhagic fever virus as shown in SEQ ID NOs: 69 to 74; amplification of SARS virus as shown in SEQ ID NOs: 75 to 80; amplification of Sabia virus as shown in SEQ ID NOs: 81 to 90; amplification of human coronavirus OC43 as shown in SEQ ID NOs: 91 to 96; amplification of Coxsackie virus A2 as shown in SEQ ID NOs: 97 to 102; amplification of Coxsackie virus A9 as shown in SEQ ID NOs: 103 to 110; amplification of enterovirus D70 as shown in SEQ ID NOs: 111 to 116; amplification of influenza C virus as shown in SEQ ID NOs: 117 to 120; amplification of Rift Valley fever virus as shown in SEQ ID NOs: 121 to 130; The primer set for amplifying human rhinovirus A as shown in SEQ ID NOs: 131 to 138; the primer set for amplifying human parechovirus type 1 as shown in SEQ ID NOs: 139 to 148; the primer set for amplifying coxsackievirus A16 as shown in SEQ ID NOs: 149 to 156; the primer set for amplifying human parainfluenza virus type 4b as shown in SEQ ID NOs: 157 to 168; the primer set for amplifying human astrovirus as shown in SEQ ID NOs: 169 to 176; the primer set for amplifying thrush coronavirus HKU12 as shown in SEQ ID NOs: 177 to 184; the primer set for amplifying munia coronavirus HKU13 as shown in SEQ ID NOs: 185 to 190; the primer set for amplifying human parechovirus type 3 as shown in SEQ ID NOs: 191 to 198;a primer set for amplifying enterovirus A71 as shown in SEQ ID NOs: 199 to 206; a primer set for amplifying human metapneumovirus as shown in SEQ ID NOs: 207 to 214; a primer set for amplifying coxsackievirus A6 as shown in SEQ ID NOs: 215 to 222; a primer set for amplifying human immunodeficiency virus as shown in SEQ ID NOs: 223 to 232; a primer set for amplifying influenza A virus H7N9 as shown in SEQ ID NOs: 233 to 248; a primer set for amplifying Ebola virus as shown in SEQ ID NOs: 249 to 258; a primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 259 to 268; a primer set for amplifying novel bunyavirus as shown in SEQ ID NOs: 269 to 278; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 279 to 288; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 289 to 290; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 291 to 293; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 294 to 295; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 296 to 297; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 298 to 301; a primer set for amplifying human respiratory syncytial virus B as shown in SEQ ID NOs: 299 to 310; a primer set for amplifying human respiratory sync a primer set for amplifying hepatitis C virus 1b subtype as shown in SEQ ID NOs: 289 to 296; a primer set for amplifying Japanese encephalitis virus as shown in SEQ ID NOs: 297 to 302; a primer set for amplifying human T-cell lymphotropic virus type II as shown in SEQ ID NOs: 303 to 312; a primer set for amplifying hepatitis A virus as shown in SEQ ID NOs: 313 to 320; a primer set for amplifying coxsackievirus B3 type as shown in SEQ ID NOs: 321 to 328; a primer set for amplifying human respiratory syncytial virus type A as shown in SEQ ID NOs: 329 to 334; a primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 335 to 342; a primer set for amplifying dengue virus type 1 as shown in SEQ ID NOs: 343 to 348; a primer set for amplifying human rhinovirus B as shown in SEQ ID NOs: 349 to 360; a primer set for amplifying human rhinovirus B as shown in SEQ ID NOs: 361 to 362; a primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 363 to 364; a primer set for amplifying human rotavirus B as shown in SEQ ID NOs: 365 to 366; a primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 367 to 368; a primer set for amplifying human rotavirus B as shown in SEQ ID NOs: 369 to 370; a primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 371 to 372; a primer set for amplifying human rotavirus A as shown in a primer set for amplifying measles virus as shown in SEQ ID NOs: 361 to 370; a primer set for amplifying rabies virus as shown in SEQ ID NOs: 371 to 378; a primer set for amplifying human parainfluenza virus type 3 as shown in SEQ ID NOs: 379 to 388; a primer set for amplifying influenza A virus H1N1 as shown in SEQ ID NOs: 389 to 400; a primer set for amplifying mumps virus as shown in SEQ ID NOs: 401 to 406; a primer set for amplifying influenza B virus as shown in SEQ ID NOs: 407 to 412; a primer set for amplifying dengue virus type 4 as shown in SEQ ID NOs: 413 to 420; a primer set for amplifying human parainfluenza virus type 2 as shown in SEQ ID NOs: 421 to 430; a primer set for amplifying human parainfluenza virus type 1 as shown in SEQ ID NOs: 431 to 440; a primer set for amplifying Eastern equine encephalitis virus as shown in SEQ ID NOs: 441 to 456;Primer groups for amplifying Banna virus as shown in SEQ ID NOs: 457-466; Primer groups for amplifying lymphochoriomeningitis virus as shown in SEQ ID NOs: 467-476; Primer groups for amplifying Hantavirus as shown in SEQ ID NOs: 477-482; Primer groups for amplifying human coronavirus NL63 as shown in SEQ ID NOs: 483-490; Primer groups for amplifying influenza A virus H5N1 as shown in SEQ ID NOs: 491-500; Primer groups for amplifying influenza A virus H3N2 as shown in SEQ ID NOs: 501-510; Primer groups for amplifying human rhinovirus C as shown in SEQ ID NOs: 511-518; Primer groups for amplifying Zika virus as shown in SEQ ID NOs: 519-524; Primer groups for amplifying enterovirus A114 as shown in SEQ ID NOs: 525-532; Primer groups for amplifying enterovirus A114 as shown in SEQ ID NOs: 534-536; Primer set for amplifying Coxsackievirus B3 as shown in SEQ ID NOs: 533 to 540; Primer set for amplifying Norovirus as shown in SEQ ID NOs: 541 to 548; Primer set for amplifying 2019 novel coronavirus as shown in SEQ ID NOs: 549 to 560; Primer set for amplifying human coronavirus HKU1 as shown in SEQ ID NOs: 561 to 568; Primer set for amplifying echovirus as shown in SEQ ID NOs: 569 to 574; Primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 575 to 580; Primer set for amplifying poliovirus 3 as shown in SEQ ID NOs: 581 to 586; Primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 587 to 594; Primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 595 to 604; Primer set for human coronavirus HKU1 as shown in SEQ ID NOs: 605 to 608. ;
[0010] In some embodiments, the compositions all have a common sequence.
[0011] In some embodiments, the universal sequence of the upstream primer is shown as SEQ ID NO:609, and the universal sequence of the downstream primer is shown as SEQ ID NO:610.
[0012] In a second aspect, the present invention provides the use of any of the above-mentioned compositions for detecting RNA viruses based on third-generation targeted sequencing in the preparation of a kit for detecting RNA viruses.
[0013] In some embodiments, detecting comprises the steps of:
[0014] S1. After extracting RNA viral nucleic acid, reverse transcription is performed to obtain cDNA;
[0015] S2, using the above composition to amplify cDNA to obtain an amplified product, and after the amplified product is treated, a library is constructed to obtain a mixed library;
[0016] S3, connecting the amplified products in the mixed library to the adapter sequence to obtain a sample to be tested;
[0017] S4. Sequence the samples to be tested and analyze the test results.
[0018] In some embodiments, in step S3, the linker sequence is an ont linker sequence.
[0019] In a third aspect, the present invention provides a kit for detecting RNA viruses based on third-generation targeted sequencing, comprising any of the above-mentioned compositions for detecting RNA viruses based on third-generation targeted sequencing.
[0020] In some embodiments, the kit further comprises at least one of the following reagents: 1) reagents required for nucleic acid extraction and reverse transcription; 2) reagents required for nucleic acid amplification; 3) reagents required for sequencing.
[0021] The beneficial effect of the present invention is that, different from the prior art, the present invention can simultaneously amplify 75 kinds of pathogenic microorganisms, and then use third-generation targeted sequencing to quickly and accurately distinguish and identify the above 75 kinds of pathogenic microorganisms. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is a graph showing the results of third-generation sequencing of a pure water sample using the composition in Example 1 of the present invention and based on third-generation targeted sequencing;
[0023] Figure 2 This is a graph showing the results of third-generation sequencing of human coronavirus 229E samples using the composition in Example 1 of the present invention and based on third-generation targeted sequencing. DETAILED DESCRIPTION
[0024] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0025] The experimental methods without specific conditions in the examples are usually carried out according to conventional conditions and conditions described in the manual, or according to conditions recommended by the manufacturer. The general equipment, materials, reagents, etc. used are all available from commercial channels unless otherwise specified.
[0026] Example 1 Design of target primers for different pathogenic microorganisms
[0027] The nucleic acid sequences of 75 pathogenic microorganisms were found on NCBI (https: / / www.ncbi.nlm.nih.gov / ), and corresponding primers were designed according to the targets of each pathogenic microorganism, as shown in Table 1 below:
[0028] Table 1 Primer sequences
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041] Example 2 Method for detecting different pathogenic microorganisms based on third-generation targeted sequencing
[0042] 1. Preparation of primer sets
[0043] The above-synthesized primer sets of 75 RNA viruses were mixed in equal volume ratio to obtain a primer set mixture.
[0044] 2. Sample preparation
[0045] The RNA of clinical samples was extracted using NAS48 of Mindray Biotechnology (for pathogenic microorganisms without clinical samples, the corresponding nucleic acid sequences were directly synthesized) to obtain the samples to be tested.
[0046] 3. Reverse transcription
[0047] The above viral RNA was transcribed into cDNA using the PureScript 1st Strand cDNA Synthesis Kit (Novizan PR111-02) reverse transcription kit.
[0048] 4. Multiplex Amplification
[0049] The above cDNA was used as a template and a primer set mixture was used for multiple PCR amplification. The amplification system is shown in Table 2 and the reaction procedure is shown in Table 3.
[0050] Table 2 Reaction system
[0051] Components volume cDNA / Positive Quality Control / Negative Quality Control 10μl <![CDATA[1 st PCR Mix]]> 10μl <![CDATA[DNase-free / RNase-free ddH 2 The]]> to 20μl
[0052] Table 3 Reaction procedure
[0053]
[0054]
[0055] 5. Purification
[0056] Prepare 75% ethanol freshly with nuclease-free water, take out the magnetic beads from 2-8°C 30 minutes in advance, equilibrate to room temperature, and vortex or invert the magnetic beads to mix thoroughly before use;
[0057] Add 22 μl of magnetic beads to the amplified product in step 4 and vortex to mix evenly;
[0058] Incubate at room temperature for 5 min to allow DNA to bind to the magnetic beads;
[0059] Centrifuge briefly, place the sample on a magnetic rack and magnetize for about 1 minute. After the solution is clear, carefully remove the supernatant.
[0060] Keep the sample on the magnetic stand, add 150 μl of freshly prepared 75% ethanol to rinse the beads, and carefully remove the supernatant;
[0061] Repeat the previous step, rinsing twice in total;
[0062] Centrifuge briefly, place the sample on a magnetic stand, and carefully remove all the supernatant;
[0063] Add 11 μl of nuclease-free water, vortex to mix evenly, and let stand at room temperature for 5 min;
[0064] Centrifuge briefly, place the sample on a magnetic stand and absorb for about 1 minute. After the solution is clear, carefully transfer the supernatant to a new eight-well plate.
[0065] The purified product can be used immediately in the next reaction or stored in a -20 °C refrigerator.
[0066] 6. Digestion
[0067] 10 μl of the purified product in step 5 was mixed with 1 μl of digestion enzyme and 9 μl of digestion solution (NoviZan T7 digestion enzyme), and digested in a metal bath at 37° C. for 5 min to obtain a digestion product.
[0068] 7. Purification
[0069] Prepare 75% ethanol freshly with nuclease-free water, take out the magnetic beads from 2-8°C 30 minutes in advance, equilibrate to room temperature, and vortex or invert the magnetic beads to mix thoroughly before use;
[0070] Add 22 μl of magnetic beads to the digestion product in step 6 and vortex to mix evenly;
[0071] Incubate at room temperature for 5 min to allow the DNA to bind to the magnetic beads.
[0072] Centrifuge briefly and place the sample on a magnetic rack for about 1 minute. After the solution is clear, carefully remove the supernatant.
[0073] Keeping the sample on the magnetic stand, add 150 μl of freshly prepared 75% ethanol to rinse the magnetic beads and carefully remove the supernatant.
[0074] Repeat the previous step for a total of 2 rinses.
[0075] Centrifuge briefly, place the sample on a magnetic stand, and carefully remove all the supernatant;
[0076] Add 17 μl of nuclease-free water, vortex to mix evenly, and let stand at room temperature for 5 min;
[0077] Centrifuge briefly, place the sample on a magnetic stand and absorb for about 1 minute. After the solution is clear, carefully transfer the supernatant to a new eight-well plate.
[0078] The purified product must be used immediately in the next reaction.
[0079] 8. Amplify the tag sequence
[0080] Using the purified product in step 7 as a template, multiplex PCR amplification was performed. The amplification system is shown in Table 4, and the reaction procedure is shown in Table 5.
[0081] Table 4 Reaction system
[0082] Components volume The purified product from the previous step 16μl Mindell Library Construction Kit B 24μl Total volume 40μl
[0083] Table 5 Reaction procedure
[0084]
[0085] 9. Purification
[0086] Prepare 75% ethanol freshly with nuclease-free water, take out the magnetic beads from 2-8°C 30 minutes in advance, equilibrate to room temperature, and vortex or invert the magnetic beads to mix thoroughly before use;
[0087] Add 40 μl of magnetic beads to the amplified product in step 8 and vortex to mix evenly;
[0088] Incubate at room temperature for 5 min to allow DNA to bind to the magnetic beads;
[0089] Centrifuge briefly, place the sample on a magnetic rack and magnetize for about 1 minute. After the solution is clear, carefully remove the supernatant.
[0090] Keep the sample on the magnetic stand, add 150 μl of freshly prepared 75% ethanol to rinse the beads, and carefully remove the supernatant;
[0091] Repeat the previous step for a total of 2 rinses.
[0092] Centrifuge briefly, place the sample on a magnetic stand, and carefully remove all the supernatant;
[0093] Add 10 μl of nuclease-free water, vortex to mix evenly, and let stand at room temperature for 5 min;
[0094] Centrifuge briefly and place the sample on a magnetic stand for about 1 minute. After the solution is clarified, 9 μl of supernatant can be obtained, which is the library.
[0095] 10. Mixed library
[0096] According to the prepared library concentration of each pathogenic microorganism, all the test objects are mixed in equal amounts, and the mixed volume of each test object and the total volume of the mixed test objects are calculated. Then, the mixture is added to a new low-adsorption centrifuge tube, oscillated to mix, and centrifuged instantaneously to obtain a mixed library.
[0097] 11. Purification
[0098] Prepare 75% ethanol freshly with nuclease-free water, take out the magnetic beads from 2-8°C 30 minutes in advance, equilibrate to room temperature, and vortex or invert the magnetic beads to mix thoroughly before use;
[0099] Add an equal volume of purified magnetic beads to the mixed test substance, oscillate to mix, centrifuge briefly, let stand at room temperature for 5 minutes, place on a magnetic stand and absorb for 1 minute, and discard the supernatant;
[0100] Keep the sample on the magnetic stand, add 150 μl of freshly prepared 75% ethanol to rinse the beads, and carefully remove the supernatant;
[0101] Repeat the previous step, rinsing twice in total;
[0102] Centrifuge briefly, place the sample on a magnetic stand, and carefully remove all the supernatant;
[0103] Add 36.5 μl of nuclease-free water, vortex to mix evenly, and let stand at room temperature for 5 minutes to obtain 35.5 μl of supernatant, which is the purified mixed analyte.
[0104] 12. Connect the sequencing adapter
[0105] The mixed sample in step 11 is connected to a sequencing adapter. The connection system is shown in Table 6, and the connection reaction is shown in Table 7.
[0106] Table 6 Connection system
[0107]
[0108]
[0109] Table 7 Ligation reaction
[0110] temperature time Heating and cooling speed Number of cycles 25℃ 10min / 1
[0111] 13. Purification
[0112] Take out the magnetic beads from 2-8℃ 30min in advance and equilibrate them to room temperature. Vortex or invert the magnetic beads to mix them thoroughly before use.
[0113] Add 40 μl of purified magnetic beads to the ligation product in step 12, vortex to mix, centrifuge briefly, let stand at room temperature for 5 minutes, place on a magnetic stand and absorb for 1 minute, and discard the supernatant;
[0114] Keep the sample on the magnetic stand, add 140 μl of 75% alcohol, and carefully remove the supernatant;
[0115] Repeat the previous step, rinsing twice in total;
[0116] Centrifuge briefly, place the sample on a magnetic stand, and carefully remove all the supernatant;
[0117] Add 8 μl of RNase-free water, flick to mix evenly, and let stand at room temperature for 5 min to obtain 7 μl of supernatant, which is the purified ligation product.
[0118] 14. Sequencing
[0119] The sequencing chip was equilibrated at room temperature for more than 30 minutes, and the sequencing chip quality inspection was performed; the inlet hole A was opened by sliding down to exhaust air, and the 1ml pipette was adjusted to 200μl, and the pipette tip was vertically aligned with the inlet hole A, and the pipette range was slowly adjusted to about 220μl to exhaust the air in the chip;
[0120] Take 800 μl of flushing solution ( ONT provides) , slowly and evenly add the solution into the sequencing chip vertically from the inlet hole A, and equilibrate the sequencing chip at room temperature for 5 minutes;
[0121] Open sample well B, take 200 μL of flushing solution with a 1 mL pipette, and add it vertically and slowly into the sequencing chip from inlet well A at a uniform speed. While doing this, pay attention to the changes in the liquid level in sample well B.
[0122] Mix 6 μl of the purified product in step 13, 18.8 μl of sequencing start solution and 12.8 μl of sequencing beads, pipette and drop them into sample well B. Close the inlet well A and sample well B, and use a 1 mL pipette to aspirate the waste liquid from the waste well C; select Start Sequencing and click Start to start sequencing.
[0123] Example 3 Detection of RNA viruses based on third-generation targeted sequencing
[0124] The pure water sample and the human coronavirus 229E sample were tested according to the method in Example 2. The results are as follows Figure 1 and 2 shown.
[0125] from Figure 1 It can be seen that there are no RNA viruses in the water, so there is no band between 200-300bp in the figure.
[0126] from Figure 2 It can be seen that the human coronavirus 229E sample has obvious bands between 200-300bp.
[0127] Furthermore, a mixed sample of 75 RNA viruses (including clinical samples and corresponding synthetic plasmids) was tested using the method in Example 2, and the results are shown in Table 8 below.
[0128] Table 8 Detection results of mixed samples of 75 RNA viruses
[0129]
[0130]
[0131]
[0132] In summary, the method based on third-generation targeted sequencing in the present invention can quickly and efficiently detect 75 pathogenic microorganisms simultaneously.
[0133] It should be noted that the above embodiments all belong to the same inventive concept, and the description of each embodiment has its own focus. For details not described in individual embodiments, reference may be made to the description in other embodiments.
[0134] The above-mentioned embodiments only express the implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A composition for detecting RNA viruses based on third-generation targeted sequencing, It is characterized in that Include at least 2 combinations of the following primer sets: A primer set for amplifying Rubella virus as shown in SEQ ID NOs: 1 to 6; A primer set for amplifying dengue virus type 2 as shown in SEQ ID NOs: 7 to 12; A primer set for amplifying dengue virus type 3 as shown in SEQ ID NOs: 13 to 18; A primer set for amplifying Coxsackievirus B6 as shown in SEQ ID NOs: 19 to 24; A primer set for amplifying human T-lymphotropic virus type I as shown in SEQ ID NOs: 25 to 30; A primer set for amplifying Coxsackievirus B2 as shown in SEQ ID NOs: 31 to 38; A primer set for amplifying tick-borne encephalitis virus as shown in SEQ ID NOs: 39 to 44; A primer set for amplifying yellow fever virus as shown in SEQ ID NOs: 45 to 48; A primer set for amplifying Coxsackievirus B5 as shown in SEQ ID NOs: 49 to 54; A primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 55-60; A primer set for amplifying hepatitis E virus as shown in SEQ ID NOs: 61 to 68; A primer set for amplifying Xinjiang hemorrhagic fever virus as shown in SEQ ID NOs: 69 to 74; A primer set for amplifying SARS virus as shown in SEQ ID NOs: 75 to 80; A primer set for amplifying Sabia virus as shown in SEQ ID NOs: 81 to 90; A primer set for amplifying human coronavirus OC43 as shown in SEQ ID NOs: 91 to 96; A primer set for amplifying Coxsackievirus A2 as shown in SEQ ID NOs: 97 to 102; A primer set for amplifying Coxsackievirus A9 as shown in SEQ ID NOs: 103 to 110; A primer set for amplifying enterovirus D70 type as shown in SEQ ID NOs: 111 to 116; A primer set for amplifying influenza C virus as shown in SEQ ID NOs: 117 to 120; A primer set for amplifying Rift Valley fever virus as shown in SEQ ID NOs: 121 to 130; A primer set for amplifying human rhinovirus A as shown in SEQ ID NOs: 131 to 138; A primer set for amplifying human parechovirus type 1 as shown in SEQ ID NOs: 139 to 148; A primer set for amplifying Coxsackievirus A16 as shown in SEQ ID NOs: 149 to 156; A primer set for amplifying human parainfluenza virus type 4b as shown in SEQ ID NOs: 157 to 168; A primer set for amplifying human astrovirus as shown in SEQ ID NOs: 169 to 176; A primer set for amplifying thrush coronavirus HKU12 as shown in SEQ ID NOs: 177-184; A primer set for amplifying Munia coronavirus HKU13 as shown in SEQ ID NOs: 185-190; A primer set for amplifying human parechovirus type 3 as shown in SEQ ID NOs: 191 to 198; A primer set for amplifying enterovirus A71 as shown in SEQ ID NOs: 199 to 206; A primer set for amplifying human metapneumovirus as shown in SEQ ID NOs: 207 to 214; A primer set for amplifying Coxsackievirus A6 as shown in SEQ ID NOs: 215 to 222; A primer set for amplifying human immunodeficiency virus as shown in SEQ ID NOs: 223 to 232; A primer set for amplifying influenza A virus H7N9 as shown in SEQ ID NOs: 233 to 248; A primer set for amplifying Ebola virus as shown in SEQ ID NOs: 249 to 258; A primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 259 to 268; A primer set for amplifying a novel bunyavirus as shown in SEQ ID NOs: 269 to 278; A primer set for amplifying human respiratory syncytial virus type B as shown in SEQ ID NOs: 279-288; A primer set for amplifying hepatitis C virus subtype 1b as shown in SEQ ID NOs: 289 to 296; A primer set for amplifying Japanese encephalitis virus as shown in SEQ ID NOs: 297 to 302; A primer set for amplifying human T-lymphotropic virus type II as shown in SEQ ID NOs: 303 to 312; A primer set for amplifying hepatitis A virus as shown in SEQ ID NOs: 313 to 320; A primer set for amplifying Coxsackievirus B3 as shown in SEQ ID NOs: 321 to 328; A primer set for amplifying human respiratory syncytial virus type A as shown in SEQ ID NOs: 329 to 334; A primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 335 to 342; A primer set for amplifying dengue virus type 1 as shown in SEQ ID NOs: 343 to 348; A primer set for amplifying human rhinovirus B as shown in SEQ ID NOs: 349-360; A primer set for amplifying measles virus as shown in SEQ ID NOs: 361 to 370; A primer set for amplifying rabies virus as shown in SEQ ID NOs: 371 to 378; A primer set for amplifying human parainfluenza virus type 3 as shown in SEQ ID NOs: 379 to 388; A primer set for amplifying influenza A virus H1N1 as shown in SEQ ID NOs: 389-400; A primer set for amplifying mumps virus as shown in SEQ ID NOs: 401 to 406; A primer set for amplifying influenza B virus as shown in SEQ ID NOs: 407 to 412; A primer set for amplifying dengue virus type 4 as shown in SEQ ID NOs: 413 to 420; A primer set for amplifying human parainfluenza virus type 2 as shown in SEQ ID NOs: 421 to 430; A primer set for amplifying human parainfluenza virus type 1 as shown in SEQ ID NOs: 431 to 440; A primer set for amplifying Eastern equine encephalitis virus as shown in SEQ ID NOs: 441-456; A primer set for amplifying Banna virus as shown in SEQ ID NOs: 457-466; A primer set for amplifying lymphochoriomeningitis virus as shown in SEQ ID NOs: 467-476; A primer set for amplifying Hantavirus as shown in SEQ ID NOs: 477-482; A primer set for amplifying human coronavirus NL63 as shown in SEQ ID NOs: 483-490; A primer set for amplifying influenza A virus H5N1 as shown in SEQ ID NOs: 491 to 500; A primer set for amplifying influenza A virus H3N2 as shown in SEQ ID NOs: 501 to 510; A primer set for amplifying human rhinovirus C as shown in SEQ ID NOs: 511 to 518; A primer set for amplifying Zika virus as shown in SEQ ID NOs: 519 to 524; A primer set for amplifying enterovirus A114 as shown in SEQ ID NOs: 525 to 532; A primer set for amplifying Coxsackievirus B3 as shown in SEQ ID NOs: 533-540; A primer set for amplifying norovirus as shown in SEQ ID NOs: 541 to 548; A primer set for amplifying 2019 novel coronavirus as shown in SEQ ID NOs: 549 to 560; A primer set for amplifying human coronavirus HKU1 as shown in SEQ ID NOs: 561-568; A primer set for amplifying echovirus as shown in SEQ ID NOs: 569-574; A primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 575 to 580; A primer set for amplifying poliovirus 3 as shown in SEQ ID NOs: 581 to 586; A primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 587 to 594; A primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 595-604; A primer set for amplifying human coronavirus HKU1 as shown in SEQ ID NOs: 605-608.
2. The composition for detecting RNA viruses based on third-generation targeted sequencing according to claim 1, It is characterized in that At least 30 combinations of primer sets were included.
3. The composition for detecting RNA viruses based on third-generation targeted sequencing according to claim 1, It is characterized in that The primer sets included are as follows: A primer set for amplifying Rubella virus as shown in SEQ ID NOs: 1 to 6; A primer set for amplifying dengue virus type 2 as shown in SEQ ID NOs: 7 to 12; A primer set for amplifying dengue virus type 3 as shown in SEQ ID NOs: 13 to 18; A primer set for amplifying Coxsackievirus B6 as shown in SEQ ID NOs: 19 to 24; A primer set for amplifying human T-lymphotropic virus type I as shown in SEQ ID NOs: 25 to 30; A primer set for amplifying Coxsackievirus B2 as shown in SEQ ID NOs: 31 to 38; A primer set for amplifying tick-borne encephalitis virus as shown in SEQ ID NOs: 39 to 44; A primer set for amplifying yellow fever virus as shown in SEQ ID NOs: 45 to 48; A primer set for amplifying Coxsackievirus B5 as shown in SEQ ID NOs: 49 to 54; A primer set for amplifying human coronavirus 229E as shown in SEQ ID NOs: 55-60; A primer set for amplifying hepatitis E virus as shown in SEQ ID NOs: 61 to 68; A primer set for amplifying Xinjiang hemorrhagic fever virus as shown in SEQ ID NOs: 69 to 74; A primer set for amplifying SARS virus as shown in SEQ ID NOs: 75 to 80; A primer set for amplifying Sabia virus as shown in SEQ ID NOs: 81 to 90; A primer set for amplifying human coronavirus OC43 as shown in SEQ ID NOs: 91 to 96; A primer set for amplifying Coxsackievirus A2 as shown in SEQ ID NOs: 97 to 102; A primer set for amplifying Coxsackievirus A9 as shown in SEQ ID NOs: 103 to 110; A primer set for amplifying enterovirus D70 type as shown in SEQ ID NOs: 111 to 116; A primer set for amplifying influenza C virus as shown in SEQ ID NOs: 117 to 120; A primer set for amplifying Rift Valley fever virus as shown in SEQ ID NOs: 121 to 130; A primer set for amplifying human rhinovirus A as shown in SEQ ID NOs: 131 to 138; A primer set for amplifying human parechovirus type 1 as shown in SEQ ID NOs: 139 to 148; A primer set for amplifying Coxsackievirus A16 as shown in SEQ ID NOs: 149 to 156; A primer set for amplifying human parainfluenza virus type 4b as shown in SEQ ID NOs: 157 to 168; A primer set for amplifying human astrovirus as shown in SEQ ID NOs: 169 to 176; A primer set for amplifying thrush coronavirus HKU12 as shown in SEQ ID NOs: 177-184; A primer set for amplifying Munia coronavirus HKU13 as shown in SEQ ID NOs: 185-190; A primer set for amplifying human parechovirus type 3 as shown in SEQ ID NOs: 191 to 198; A primer set for amplifying enterovirus A71 as shown in SEQ ID NOs: 199 to 206; A primer set for amplifying human metapneumovirus as shown in SEQ ID NOs: 207 to 214; A primer set for amplifying Coxsackievirus A6 as shown in SEQ ID NOs: 215 to 222; A primer set for amplifying human immunodeficiency virus as shown in SEQ ID NOs: 223 to 232; A primer set for amplifying influenza A virus H7N9 as shown in SEQ ID NOs: 233 to 248; A primer set for amplifying Ebola virus as shown in SEQ ID NOs: 249 to 258; A primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 259 to 268; A primer set for amplifying a novel bunyavirus as shown in SEQ ID NOs: 269 to 278; A primer set for amplifying human respiratory syncytial virus type B as shown in SEQ ID NOs: 279-288; A primer set for amplifying hepatitis C virus subtype 1b as shown in SEQ ID NOs: 289 to 296; A primer set for amplifying Japanese encephalitis virus as shown in SEQ ID NOs: 297 to 302; A primer set for amplifying human T-lymphotropic virus type II as shown in SEQ ID NOs: 303 to 312; A primer set for amplifying hepatitis A virus as shown in SEQ ID NOs: 313 to 320; A primer set for amplifying Coxsackievirus B3 as shown in SEQ ID NOs: 321 to 328; A primer set for amplifying human respiratory syncytial virus type A as shown in SEQ ID NOs: 329 to 334; A primer set for amplifying human rotavirus A as shown in SEQ ID NOs: 335 to 342; A primer set for amplifying dengue virus type 1 as shown in SEQ ID NOs: 343 to 348; A primer set for amplifying human rhinovirus B as shown in SEQ ID NOs: 349-360; A primer set for amplifying measles virus as shown in SEQ ID NOs: 361 to 370; A primer set for amplifying rabies virus as shown in SEQ ID NOs: 371 to 378; A primer set for amplifying human parainfluenza virus type 3 as shown in SEQ ID NOs: 379 to 388; A primer set for amplifying influenza A virus H1N1 as shown in SEQ ID NOs: 389-400; A primer set for amplifying mumps virus as shown in SEQ ID NOs: 401 to 406; A primer set for amplifying influenza B virus as shown in SEQ ID NOs: 407 to 412; A primer set for amplifying dengue virus type 4 as shown in SEQ ID NOs: 413 to 420; A primer set for amplifying human parainfluenza virus type 2 as shown in SEQ ID NOs: 421 to 430; A primer set for amplifying human parainfluenza virus type 1 as shown in SEQ ID NOs: 431 to 440; A primer set for amplifying Eastern equine encephalitis virus as shown in SEQ ID NOs: 441-456; A primer set for amplifying Banna virus as shown in SEQ ID NOs: 457-466; A primer set for amplifying lymphochoriomeningitis virus as shown in SEQ ID NOs: 467-476; A primer set for amplifying Hantavirus as shown in SEQ ID NOs: 477-482; A primer set for amplifying human coronavirus NL63 as shown in SEQ ID NOs: 483-490; A primer set for amplifying influenza A virus H5N1 as shown in SEQ ID NOs: 491 to 500; A primer set for amplifying influenza A virus H3N2 as shown in SEQ ID NOs: 501 to 510; A primer set for amplifying human rhinovirus C as shown in SEQ ID NOs: 511 to 518; A primer set for amplifying Zika virus as shown in SEQ ID NOs: 519 to 524; A primer set for amplifying enterovirus A114 as shown in SEQ ID NOs: 525 to 532; A primer set for amplifying Coxsackievirus B3 as shown in SEQ ID NOs: 533-540; A primer set for amplifying norovirus as shown in SEQ ID NOs: 541 to 548; A primer set for amplifying 2019 novel coronavirus as shown in SEQ ID NOs: 549 to 560; A primer set for amplifying human coronavirus HKU1 as shown in SEQ ID NOs: 561-568; A primer set for amplifying echovirus as shown in SEQ ID NOs: 569-574; A primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 575 to 580; A primer set for amplifying poliovirus 3 as shown in SEQ ID NOs: 581 to 586; A primer set for amplifying poliovirus 1 as shown in SEQ ID NOs: 587 to 594; A primer set for amplifying enterovirus D68 as shown in SEQ ID NOs: 595-604; A primer set for amplifying human coronavirus HKU1 as shown in SEQ ID NOs: 605-608.
4. A composition for detecting RNA viruses based on third-generation targeted sequencing according to any one of claims 1 to 3, It is characterized in that The compositions all carry a common sequence.
5. The composition for detecting RNA viruses based on third-generation targeted sequencing according to claim 4, It is characterized in that The universal sequence of the upstream primer is shown in SEQ ID NO:609, and the universal sequence of the downstream primer is shown in SEQ ID NO:
610.
6. Use of the composition for detecting RNA viruses based on third-generation targeted sequencing according to any one of claims 1 to 5 in the preparation of a kit for detecting RNA viruses.
7. The use according to claim 6, It is characterized in that The detection comprises the following steps: S1. After extracting RNA viral nucleic acid, reverse transcription is performed to obtain cDNA; S2. Amplifying the cDNA using the composition according to any one of claims 1 to 5 to obtain an amplified product, and constructing a library after treating the amplified product to obtain a mixed library; S3, connecting the amplified products in the mixed library to the adapter sequence to obtain a sample to be tested; S4. Sequencing the sample to be tested and analyzing the test results.
8. The use according to claim 7, It is characterized in that In step S3, the linker sequence is an ont linker sequence.
9. A kit for detecting RNA viruses based on third-generation targeted sequencing. It is characterized in that A composition for detecting RNA viruses based on third-generation targeted sequencing comprising any one of claims 1-5.
10. The kit according to claim 9, It is characterized in that Also includes at least one of the following reagents: 1) Reagents required for nucleic acid extraction and reverse transcription; 2) Reagents required for nucleic acid amplification; 3) Reagents required for sequencing.
